Cure of Histiocytic Lymphoma
- JOHN E. ULTMANN, M.D.
Excerpt
The curability of patients with Hodgkin's disease of all stages improved from a 5-year survival rate in 1940 of 6% to a 5-year actuarial estimated survival rate in 1970 of over 75% (1). During this same 30-year period the survival statistics reported for "reticulum cell sarcoma" (the diagnostic entity coded in national statistical analyses before acceptance of the term "histiocytic lymphoma") remained at a dismal 5-year survival rate of 18% or lower (2).
The knowledge gained from the cure of Hodgkin's disease together with new conceptual approaches and the development of new drugs and drug combinations have permitted novel approaches
This 100-word excerpt has been provided in the absence of an abstract.
Article and Author Information
-
Grant support: in part by grant CA-14599, U. S. Public Health Service; the Joanne Heppes Fund, the Goldblatt Brothers Employees Nathan Goldblatt Cancer Research Fund, and the Jean Heiman Fund.
Most Read
